anti-RNA Polymerase II CTD repeat YSPTSPS phospho (Ser5) antibody [CTD 4H8]
![anti-RNA Polymerase II CTD repeat YSPTSPS phospho (Ser5) antibody [CTD 4H8]](/upload/image/products/ARG10661_WB_1_210_205.jpg)
![anti-RNA Polymerase II CTD repeat YSPTSPS phospho (Ser5) antibody [CTD 4H8]](/upload/image/products/ARG10661_WB_1.jpg)
Key features and details
- 产品描述:
- 反应物种:
- 应用:
- 宿主:
- 克隆:
- 克隆号:
- 同位型:
- 靶点名称:
- 抗原物种:
-
Brand:
CAT.NO. : ARG10661
US＄ Please choose
US＄ Please choose
Size:
Trail, Bulk size or Custom requests Please contact us
*产品价格可能会有所调整，请以品牌方官网实时更新的价格为准，以确保准确性。
Product Details
概述
| 产品描述 | Mouse Monoclonal antibody [CTD 4H8] recognizes RNA Polymerase II CTD repeat YSPTSPS phospho (Ser5) |
|---|---|
| 反应物种 | Hu, Ms, Rat, AGMK, Arabi, Ce, Dm, S. cerevisiae, S. pombe |
| 应用 | ChIP, ChIP-seq, FACS, ICC/IF, IHC-P, IP, WB |
| 宿主 | Mouse |
| 克隆 | Monoclonal |
| 克隆号 | CTD 4H8 |
| 同位型 | IgG1 |
| 靶点名称 | RNA Polymerase II CTD repeat YSPTSPS |
| 抗原物种 | Human |
| 抗原 | Synthetic peptide: 10 repeats of YSPTSPS (Phosphorylated on Ser5). |
| 偶联标记 | Un-conjugated |
| 別名 | EC 2.7.7.6; RPO2; RPB1; RPOL2; POLRA; DNA-directed RNA polymerase II subunit A; hsRPB1; EC 2.7.7.48; RNA-directed RNA polymerase II subunit RPB1; hRPB220; POLR2; RNA polymerase II subunit B1; DNA-directed RNA polymerase II subunit RPB1; RpIILS; RPBh1; DNA-directed RNA polymerase III largest subunit |
应用说明
| 应用建议 |
| ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 应用说明 | * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. | ||||||||||||||||
| 阳性对照 | HeLa cell line. |
属性
| 形式 | Liquid |
|---|---|
| 纯化 | Affinity purification with immunogen. |
| 缓冲液 | PBS and 0.02% Sodium azide. |
| 抗菌剂 | 0.02% Sodium azide |
| 存放说明 | For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. |
| 注意事项 | For laboratory research only, not for drug, diagnostic or other use. |
生物信息
| 数据库连接 | Swiss-port # P08775 Mouse DNA-directed RNA polymerase II subunit RPB1 Swiss-port # P24928 Human DNA-directed RNA polymerase II subunit RPB1 |
|---|---|
| 基因名称 | POLR2A |
| 全名 | polymerase (RNA) II (DNA directed) polypeptide A, 220kDa |
| 背景介绍 | This gene encodes the largest subunit of RNA polymerase II, the polymerase responsible for synthesizing messenger RNA in eukaryotes. The product of this gene contains a carboxy terminal domain composed of heptapeptide repeats that are essential for polymerase activity. These repeats contain serine and threonine residues that are phosphorylated in actively transcribing RNA polymerase. In addition, this subunit, in combination with several other polymerase subunits, forms the DNA binding domain of the polymerase, a groove in which the DNA template is transcribed into RNA. [provided by RefSeq, Jul 2008] |
| 生物功能 | DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Largest and catalytic component of RNA polymerase II which synthesizes mRNA precursors and many functional non-coding RNAs. Forms the polymerase active center together with the second largest subunit. Pol II is the central component of the basal RNA polymerase II transcription machinery. It is composed of mobile elements that move relative to each other. RPB1 is part of the core element with the central large cleft, the clamp element that moves to open and close the cleft and the jaws that are thought to grab the incoming DNA template. At the start of transcription, a single-stranded DNA template strand of the promoter is positioned within the central active site cleft of Pol II. A bridging helix emanates from RPB1 and crosses the cleft near the catalytic site and is thought to promote translocation of Pol II by acting as a ratchet that moves the RNA-DNA hybrid through the active site by switching from straight to bent conformations at each step of nucleotide addition. During transcription elongation, Pol II moves on the template as the transcript elongates. Elongation is influenced by the phosphorylation status of the C-terminal domain (CTD) of Pol II largest subunit (RPB1), which serves as a platform for assembly of factors that regulate transcription initiation, elongation, termination and mRNA processing. Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicate and transcriptase for the viral RNA circular genome. [UniProt] |
| 预测分子量 | 217 kDa |
| 翻译后修饰 | The tandem heptapeptide repeats in the C-terminal domain (CTD) can be highly phosphorylated. The phosphorylation activates Pol II. Phosphorylation occurs mainly at residues 'Ser-2' and 'Ser-5' of the heptapeptide repeat and is mediated, at least, by CDK7 and CDK9. CDK7 phosphorylation of POLR2A associated with DNA promotes transcription initiation by triggering dissociation from DNA. Phosphorylation also takes place at 'Ser-7' of the heptapeptide repeat, which is required for efficient transcription of snRNA genes and processing of the transcripts. The phosphorylation state is believed to result from the balanced action of site-specific CTD kinases and phosphatases, and a 'CTD code' that specifies the position of Pol II within the transcription cycle has been proposed. Dephosphorylated by the protein phosphatase CTDSP1. Among tandem heptapeptide repeats of the C-terminal domain (CTD) some do not match the Y-S-P-T-S-P-S consensus, the seventh serine residue 'Ser-7' being replaced by a lysine. 'Lys-7' in these non-consensus heptapeptide repeats can be alternatively acetylated, methylated and dimethylated. EP300 is one of the enzyme able to acetylate 'Lys-7'. Acetylation at 'Lys-7' of non-consensus heptapeptide repeats is associated with 'Ser-2' phosphorylation and active transcription. Regulates initiation or early elongation steps of transcription specially for inducible genes. Methylated at Arg-1810 prior to transcription initiation when the CTD is hypophosphorylated, phosphorylation at Ser-1805 and Ser-1808 preventing this methylation. Symmetrically or asymmetrically dimethylated at Arg-1810 by PRMT5 and CARM1 respectively. Symmetric or asymmetric dimethylation modulates interactions with CTD-binding proteins like SMN1/SMN2 and TDRD3. SMN1/SMN2 interacts preferentially with the symmetrically dimethylated form while TDRD3 interacts with the asymmetric form. Through the recruitment of SMN1/SMN2, symmetric dimethylation is required for resolving RNA-DNA hybrids created by RNA polymerase II, that form R-loop in transcription terminal regions, an important step in proper transcription termination. CTD dimethylation may also facilitate the expression of select RNAs. Among tandem heptapeptide repeats of the C-terminal domain (CTD) some do not match the Y-S-P-T-S-P-S consensus, the seventh serine residue 'Ser-7' being replaced by a lysine. 'Lys-7' in these non-consensus heptapeptide repeats can be alternatively acetylated, methylated, dimethylated and trimethylated. Methylation occurs in the earliest transcription stages and precedes or is concomitant to 'Ser-5' and 'Ser-7' phosphorylation. Dimethylation and trimehtylation at 'Lys-7' of non-consensus heptapeptide repeats are exclusively associated with phosphorylated CTD. Ubiquitinated by WWP2 leading to proteasomal degradation (By similarity). Following UV treatment, the elongating form of RNA polymerase II (RNA pol IIo) is ubiquitinated on UV damage sites without leading to degradation: ubiquitination is facilitated by KIAA1530/UVSSA and promotes RNA pol IIo backtracking to allow access to the nucleotide excision repair machinery. |
检测图片 (1)
ARG10661 anti-RNA Polymerase II CTD repeat YSPTSPS phospho (Ser5) antibody [CTD 4H8] WB image
Western blot: RNAP II stained with ARG10661 anti-RNA Polymerase II CTD repeat YSPTSPS phospho (Ser5) antibody [CTD 4H8] at 1:1000 dilution.
New Products
